Imagine waking up after a life-threatening brain bleed, hoping for the best, but fearing the invisible threat of delayed brain injury. This study looked at 80 patients admitted to a top neurocritical care center who had suffered an aneurysmal subarachnoid hemorrhage. Researchers wanted to know if chemicals produced by gut bacteria could warn doctors before serious problems appeared. They found that patients who ended up with poor function three months later had significantly lower levels of certain acids and tryptophan in their blood early on. Those with delayed brain ischemia also showed these low levels, especially a specific compound called indole-3-propionic acid on day nine. These chemicals act like messengers between the gut and the brain, potentially signaling trouble before it becomes obvious on a scan. However, because this was an observational study, we only know these markers are linked to bad outcomes, not that they cause them. The science is still figuring out exactly how these signals work in the human body.
Gut Metabolite Levels Associate with Outcomes After Aneurysmal Subarachnoid HemorrhageCan early blood tests predict brain injury after a severe brain bleed?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note associations between gut metabolites and outcomes in aSAH; clinical utility remains unproven.
This prospective observational cohort study followed 80 consecutive patients with aneurysmal subarachnoid hemorrhage admitted to a tertiary neurocritical care center for 3 months. The study analyzed temporal dynamics of serum gut microbiota-derived metabolites, including short-chain fatty acids and tryptophan-related compounds, without a specific intervention or comparator. The primary outcome was functional status at 3 months assessed by the modified Rankin Scale (mRS), and delayed cerebral ischemia (DCI) was diagnosed per consensus criteria.
Lower Day 1 levels of propionic, isobutyric, and isovaleric acids were significantly associated with an unfavorable 3-month outcome (mRS 4-6). Reduced tryptophan levels at both Day 1 and Day 9, and markedly lower indole-3-propionic acid (IPA) concentrations on Day 9, were also linked to poor outcomes. For DCI, associations were observed with reduced tryptophan and propionic acid levels on both days and a pronounced decrease in IPA on Day 9. Tryptophan and propionic acid demonstrated excellent discriminative performance for outcomes, with reported AUCs up to 0.99.
In multivariable models, low Day 1 propionic acid and low Day 9 IPA independently predicted unfavorable outcome, while Day 9 tryptophan, IPA, and propionic acid independently predicted DCI. Safety and tolerability data were not reported. Key limitations include the observational design, which precludes establishing causation, and the lack of reported absolute numbers, effect sizes, or p-values/confidence intervals for most associations. The single-center setting and specific patient population also limit generalizability.
These findings position specific gut metabolites as promising associative biomarkers for secondary brain injury after subarachnoid hemorrhage. However, the evidence remains preliminary, and the clinical utility of these markers for prognosis or guiding therapy is not yet established.
What this means for you:
Low levels of certain gut-derived chemicals in the blood are linked to worse recovery after a brain bleed, but this study only shows a connection, not a cause. More on Aneurysmal Subarachnoid Hemorrhage
Early serum metabolomics distinguished delayed cerebral ischemia from non-DCI aneurysmal subarachnoid hemorrhage in a small retrospective cohort
A Simple Blood Test Could Predict a Dangerous Stroke Complication
This retrospective cohort study evaluated early serum metabolomics in 44 patients with aneurysmal subarachnoid hemorrhage (aSAH), comparing …
For patients who survive a burst brain aneurysm, a new discovery could help doctors see trouble coming days in advance and act to prevent fu…
Ensemble machine learning models show best discriminative performance for predicting DCI after aneurysmal SAH
Machine learning models show promise for predicting brain complications after aneurysm rupture
A systematic review and meta-analysis of 29 studies involving 10,000 patients with aneurysmal subarachnoid hemorrhage found that ensemble ma…
Machine learning models can predict dangerous brain complications after aneurysm rupture with moderate accuracy, but real-world testing is s…
Pre-admission statin use linked to better 30-day outcomes after aneurysmal SAH
Pre-admission statin use linked to better 30-day outcomes in brain bleed patients
This observational study of 1,431 patients with aneurysmal subarachnoid hemorrhage found that pre-admission statin use was associated with a…
Using statins before a brain bleed may improve early recovery chances, but benefits did not last to 90 days in this real-world study.
Five-variable admission model predicts 90-day outcomes in 245 aneurysmal subarachnoid hemorrhage patients
New model predicts recovery after aneurysmal subarachnoid hemorrhage
This single-center cohort study evaluated an admission-based five-variable model in 245 consecutive treatment-eligible patients with aneurys…
A simple 5-factor model at hospital admission accurately predicts 90-day recovery after bleeding stroke.
View Original Abstract ↓
BackgroundDelayed cerebral ischemia (DCI) remains a major determinant of poor outcome after aneurysmal subarachnoid hemorrhage (aSAH). Growing evidence suggests that gut microbiota–derived metabolites, including short-chain fatty acids (SCFAs) and tryptophan-related indole compounds, modulate neuroinflammation and cerebrovascular vulnerability. However, their temporal dynamics and clinical relevance after aSAH are insufficiently characterized.MethodsIn this prospective observational study, 80 consecutive patients with aSAH were enrolled at a tertiary neurocritical care center. Serum concentrations of SCFAs (propionic, butyric, isobutyric, valeric, isovaleric, caproic acids) and tryptophan-derived metabolites (tryptophan, indole-3-propionic acid [IPA], indole-3-acetic acid, indole-3-lactic acid) were quantified using LC–MS on Day 1 and Day 9 after hemorrhage. Functional outcome at 3 months was assessed using the modified Rankin Scale (mRS), and DCI was diagnosed according to consensus criteria. Associations were analyzed using non-parametric statistics, ROC analyses, and multivariable logistic regression adjusted for established clinical confounders.ResultsPatients with unfavorable 3-month outcomes (mRS 4–6) showed significantly lower Day 1 levels of propionic, isobutyric, and isovaleric acids, persistently reduced tryptophan at both time points, and markedly lower IPA concentrations on Day 9. DCI was associated with reduced tryptophan and propionic acid levels on both days and a pronounced decrease in IPA on Day 9. Tryptophan and propionic acid demonstrated excellent discriminative performance for outcome and DCI (AUCs up to 0.99). In multivariable models, low Day 1 propionic acid and low Day 9 IPA independently predicted unfavorable outcome, while Day 9 tryptophan, IPA, and propionic acid independently predicted DCI.ConclusionDistinct temporal alterations in gut microbiota–derived metabolites after aSAH are strongly associated with functional outcome and DCI. SCFAs and tryptophan-related metabolites—particularly propionic acid, tryptophan, and IPA—emerge as promising biomarkers and potential mechanistic mediators in secondary brain injury after aSAH.
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …